{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T19:38:59Z","timestamp":1789587539554,"version":"build-2803163510"},"reference-count":29,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1124\/jpet.111.185876","type":"journal-article","created":{"date-parts":[[2011,8,10]],"date-time":"2011-08-10T22:42:53Z","timestamp":1313016173000},"page":"618-623","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":62,"title":["Neuroprotection with a Brain-Penetrating Biologic Tumor Necrosis Factor Inhibitor"],"prefix":"10.1016","volume":"339","author":[{"given":"Qing-Hui","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachita","family":"Sumbria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric Ka-Wai","family":"Hui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff Zhiqiang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben J.","family":"Boado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William M.","family":"Pardridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.111.185876_bib1","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1124\/jpet.109.165092","article-title":"Drug targeting of erythropoietin across the primate blood-brain barrier with an IgG molecular Trojan horse","volume":"333","author":"Boado","year":"2010","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.111.185876_bib2","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1002\/bit.22135","article-title":"Engineering and expression of a chimeric transferrin receptor monoclonal antibody for blood-brain barrier delivery in the mouse","volume":"102","author":"Boado","year":"2009","journal-title":"Biotechnol Bioeng"},{"key":"10.1124\/jpet.111.185876_bib3","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/bit.21120","article-title":"Humanization of anti-human insulin receptor antibody for drug targeting across the human blood-brain barrier","volume":"96","author":"Boado","year":"2007","journal-title":"Biotechnol Bioeng"},{"key":"10.1124\/jpet.111.185876_bib4","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1126\/science.1071924","article-title":"TNF-R1 signaling: a beautiful pathway","volume":"296","author":"Chen","year":"2002","journal-title":"Science"},{"key":"10.1124\/jpet.111.185876_bib5","doi-asserted-by":"crossref","first-page":"3303","DOI":"10.1182\/blood-2008-02-138073","article-title":"Activation of natural regulatory T cells by IgG Fc-derived peptide \u201cTregitopes.\u201d","volume":"112","author":"De Groot","year":"2008","journal-title":"Blood"},{"key":"10.1124\/jpet.111.185876_bib6","first-page":"2868","article-title":"Immune tolerance improves the efficacy of enzyme replacement therapy in canine mucopolysaccharidosis I","volume":"118","author":"Dickson","year":"2008","journal-title":"J Clin Invest"},{"key":"10.1124\/jpet.111.185876_bib7","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1111\/j.1471-4159.2004.02399.x","article-title":"Genetic ablation of tumor necrosis factor-\u03b1 (TNF-\u03b1) and pharmacological inhibition of TNF-synthesis attenuates MPTP toxicity in mouse striatum","volume":"89","author":"Ferger","year":"2004","journal-title":"J Neurochem"},{"key":"10.1124\/jpet.111.185876_bib8","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.brainres.2010.06.059","article-title":"Intravenous treatment of experimental Parkinson\u2019s disease in the mouse with an IgG-GDNF fusion protein that penetrates the blood-brain barrier","volume":"1352","author":"Fu","year":"2010","journal-title":"Brain Res"},{"key":"10.1124\/jpet.111.185876_bib9","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1083\/jcb.200705042","article-title":"Deletion of tumor necrosis factor death receptor inhibits amyloid beta generation and prevents learning and memory deficits in Alzheimer\u2019s mice","volume":"178","author":"He","year":"2007","journal-title":"J Cell Biol"},{"key":"10.1124\/jpet.111.185876_bib10","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.eurpsy.2008.03.013","article-title":"Depression, comorbidities and the TNF-\u03b1 system","volume":"23","author":"Himmerich","year":"2008","journal-title":"Eur Psychiatry"},{"key":"10.1124\/jpet.111.185876_bib11","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1021\/mp900103n","article-title":"Tumor necrosis factor receptor-IgG fusion protein for targeted-drug delivery across the human blood-brain barrier","volume":"6","author":"Hui","year":"2009","journal-title":"Mol Pharm"},{"key":"10.1124\/jpet.111.185876_bib12","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1002\/bit.20880","article-title":"Comparison of cell lines for stable production of fucose-negative antibodies with enhanced ADCC","volume":"94","author":"Kanda","year":"2006","journal-title":"Biotechnol Bioeng"},{"key":"10.1124\/jpet.111.185876_bib13","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S0022-3565(24)35388-1","article-title":"Targeting rat anti-mouse transferrin receptor monoclonal antibodies through blood-brain barrier in mouse","volume":"292","author":"Lee","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.111.185876_bib14","article-title":"Peripheral inflammation increases the damage in animal models of nigrostriatal dopaminergic neurodegeneration: possible implication in Parkinson\u2019s disease incidence","volume":"2011","author":"Machado","year":"2011","journal-title":"Parkinsons Dis"},{"key":"10.1124\/jpet.111.185876_bib15","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.ejpain.2008.08.001","article-title":"Effects of Etanercept and Minocycline in a rat model of spinal cord injury","volume":"13","author":"Marchand","year":"2009","journal-title":"Eur J Pain"},{"key":"10.1124\/jpet.111.185876_bib16","doi-asserted-by":"crossref","first-page":"9365","DOI":"10.1523\/JNEUROSCI.1504-06.2006","article-title":"Blocking soluble tumor necrosis factor signaling with dominant-negative tumor necrosis factor inhibitor attenuates loss of dopaminergic neurons in models of Parkinson\u2019s disease","volume":"26","author":"McCoy","year":"2006","journal-title":"J Neurosci"},{"key":"10.1124\/jpet.111.185876_bib17","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1002\/1529-0131(200112)44:12<2819::AID-ART469>3.0.CO;2-2","article-title":"Association of tumor necrosis factor receptor type II polymorphism 196R with systemic lupus erythematosus in the Japanese: molecular and functional analysis","volume":"44","author":"Morita","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1124\/jpet.111.185876_bib18","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3109\/10611860903548354","article-title":"Biopharmaceutical drug targeting to the brain","volume":"18","author":"Pardridge","year":"2010","journal-title":"J Drug Target"},{"key":"10.1124\/jpet.111.185876_bib19","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1023\/A:1016244500596","article-title":"Human insulin receptor monoclonal antibody undergoes high affinity binding to human brain capillaries in vitro and rapid transcytosis through the blood-brain barrier in vivo in the primate","volume":"12","author":"Pardridge","year":"1995","journal-title":"Pharm Res"},{"key":"10.1124\/jpet.111.185876_bib20","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1084\/jem.174.6.1483","article-title":"A tumor necrosis factor (TNF) receptor-IgG heavy chain chimeric protein as a bivalent antagonist of TNF activity","volume":"174","author":"Peppel","year":"1991","journal-title":"J Exp Med"},{"key":"10.1124\/jpet.111.185876_bib21","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1124\/jpet.301.2.418","article-title":"Binding and functional comparisons of two types of tumor necrosis factor antagonists","volume":"301","author":"Scallon","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.111.185876_bib22","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1006\/cyto.1995.0091","article-title":"Functional comparisons of different tumour necrosis factor receptor\/IgG fusion proteins","volume":"7","author":"Scallon","year":"1995","journal-title":"Cytokine"},{"key":"10.1124\/jpet.111.185876_bib23","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/jcbfm.1994.76","article-title":"Closed head injury triggers early production of TNF \u03b1 and IL-6 by brain tissue","volume":"14","author":"Shohami","year":"1994","journal-title":"J Cereb Blood Flow Metab"},{"key":"10.1124\/jpet.111.185876_bib24","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1093\/jb\/mvj207","article-title":"Enhanced Fc-dependent cellular cytotoxicity of Fc fusion proteins derived from TNF receptor II and LFA-3 by fucose removal from Asn-linked oligosaccharides","volume":"140","author":"Shoji-Hosaka","year":"2006","journal-title":"J Biochem"},{"key":"10.1124\/jpet.111.185876_bib25","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1096\/fj.02-0216fje","article-title":"Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: implications for Parkinson\u2019s disease","volume":"16","author":"Sriram","year":"2002","journal-title":"FASEB J"},{"key":"10.1124\/jpet.111.185876_bib26","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.drudis.2009.10.002","article-title":"The TNF superfamily in 2009: new pathways, new indications, and new drugs","volume":"14","author":"Tansey","year":"2009","journal-title":"Drug Discov Today"},{"key":"10.1124\/jpet.111.185876_bib27","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.nbd.2006.11.012","article-title":"TNF-\u03b1 knockout and minocycline treatment attenuates blood-brain barrier leakage in MPTP-treated mice","volume":"26","author":"Zhao","year":"2007","journal-title":"Neurobiol Dis"},{"key":"10.1124\/jpet.111.185876_bib28","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1124\/dmd.110.036012","article-title":"Brain-penetrating tumor necrosis factor decoy receptor in the mouse","volume":"39","author":"Zhou","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/jpet.111.185876_bib29","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1124\/dmd.111.038349","article-title":"Chronic dosing of mice with a transferrin receptor monoclonal antibody-glial-derived neurotrophic factor fusion protein","volume":"39","author":"Zhou","year":"2011","journal-title":"Drug Metab Dispos"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524466299?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524466299?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.111.185876","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T18:49:20Z","timestamp":1743187760000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524466299"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,11]]}},"alternative-id":["S0022356524466299"],"URL":"https:\/\/doi.org\/10.1124\/jpet.111.185876","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2011,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neuroprotection with a Brain-Penetrating Biologic Tumor Necrosis Factor Inhibitor","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.111.185876","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2011 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}